Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - SPECTRUM PHARMACEUTICALS INC | stradlingyocca20151130.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 30, 2015
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-35006 | 93-0979187 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
11500 S. Eastern Ave., Ste. 240, Henderson, NV | 89052 | |
(Address of Principal Executive Offices) | (Zip Code) | |
Registrant's telephone number, including area code: (702) 835-6300
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 | Other Events |
On November 30, 2015, Spectrum Pharmaceuticals, Inc. (the “Company”) received the attached letter from the Securities and Exchange Commission (“SEC”), indicating that the SEC has concluded its investigation; no action is being taken against the Company.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | |
99.1 | SEC letter dated November 30, 2015 | |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Spectrum Pharmaceuticals, Inc. | ||
Date: December 7, 2015 | By: | /s/ Kurt A. Gustafson |
Kurt A. Gustafson | ||
Executive Vice President and Chief | ||
Financial Officer | ||
EXHIBIT INDEX
Exhibit No. | Description | |
99.1 | SEC letter dated November 30, 2015. | |